| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 536230700 | Encodes a microbial polypeptide | 27 |
| 20080287664 | HSP60 FROM ARTHROBACTER - The hsp60 gene from a strain of | 11-20-2008 |
| 20090099349 | Biomarkers For Toxic Algae - The present invention is directed toward biomarkers that identify characteristics of algae. The invention is further directed toward biomarkers that serve to identify algae species and strains of algae species as well as detect the presence of algal toxins. Additional embodiments feature methods utilizing algal biomarkers and polypeptides that can serve as biomarkers. | 04-16-2009 |
| 20090137788 | USPA1 AND USPA2 ANTIGENS OF MORAXELLA CATARRHALIS - The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of | 05-28-2009 |
| 20100016572 | Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen - The present invention provides a polyeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, | 01-21-2010 |
| 20100121042 | CHIMERA BOTULINUM TOXIN TYPE E - The present invention relates to a toxin comprising a modified light chain of a botulinum toxin type E, wherein the modified light chain comprises amino acid sequence PFVNKQFN (SEQ ID NO: 120) at the N-terminus, and amino acid sequence xExxxLL (SEQ ID NO: 112) at the C-terminus, wherein x is any amino acid. | 05-13-2010 |
| 20100273995 | Polynucleotides and their use for detecting resistance to streptogramin a or to streptogramin B and related compounds - The present invention pertains to polynucleotides derived from staphylococcal genes encoding resistance to streptogramin A or to streptogramin B and chemically related compounds. This invention also relates to the use of the polynucleotides as oligonucleotide primers or probes for detecting Staphylococcal strains that are resistant to streptogramin A or to streptogramin B and related compounds in a biological sample. In another embodiment, the present invention is directed to the full length coding sequences of the staphylococcal genes encoding for resistance to streptogramin A or to streptogramin B from | 10-28-2010 |
| 20100331537 | NOVEL SURFACE ANTIGEN - The invention provides a novel surface polypeptide from | 12-30-2010 |
| 20110144318 | Selected nucleotide sequences isolated from pathogenic strains of haemophilus influenzae - A DNA sequence of | 06-16-2011 |
| 20120220760 | COMPOSITION COMPRISING RNA DERIVED FROM LACTIC ACID BACTERIUM AS EFFECTIVE COMPONENT - A composition has an immunomodulation action, and comprises an RNA derived from a lactic acid bacterium as an effective component. Alternatively, a composition has a cytokine production-modulating action, and includes an RNA derived from a lactic acid bacterium as an effective component. | 08-30-2012 |
| 20130158245 | Detecting and Typing of Bacterial Strains - Methods for the detection and typing of bacterial strains from food products and dietary supplements, environmental samples, in vivo/in vitro samples, and for studying the natural diversity of the species are disclosed. Potential applications also include product development and/or detection and differentiation of new bacterial strains. | 06-20-2013 |
| 20130331559 | NOVEL TARGETS FOR THE IDENTIFICATION OF ANTIBIOTICS THAT ARE NOT SUSCEPTIBLE TO ANTIBIOTIC RESISTANCE - To identify conserved and variable regions of the 16 S rRNA, an instant evolution experiment was performed on the entire 16 S rRNA. Analysis of these mutants identified regions that are required for function. These conserved sequences may be used as targets for pharmaceuticals that are taxonomically specific and which are refractory to the development of drug resistance. | 12-12-2013 |
| 20140046048 | MOLECULAR STANDARDS FOR MICROBIAL PATHOGENS - A method for constructing a consensus sequence from a sequence alignment. The consensus sequence may be used to generate molecular standards that may substitute for genomic DNA in various assays. Since a molecular standard cannot have unresolved bases, the method removes less informative sequences to resolve all positions in the alignment. Also includes several sequences from pathogenic waterborne species that were constructed according to the method. | 02-13-2014 |
| 20140046049 | AXMI-205 PESTICIDAL GENE AND METHOD FOR ITS USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated pesticidal nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2, 3, or 4, the nucleotide sequence set forth in SEQ ID NO:1, 9, 10, or 11, as well as variants and fragments thereof. | 02-13-2014 |
| 536230720 | Viral protein | 14 |
| 20080262211 | HEPATITIS-C VIRUS TYPE 4, 5 AND 6 - The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof. | 10-23-2008 |
| 20080269473 | Method - A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pol proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pol proteins is codon optimised for expression in the producer cell. | 10-30-2008 |
| 20100137571 | DENGUE SEROTYPE 1 ATTENUATED STRAIN - The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain. | 06-03-2010 |
| 20100174057 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 07-08-2010 |
| 20100273996 | Method - A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pot proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pot proteins is codon optimised for expression in the producer cell. | 10-28-2010 |
| 20110040079 | Infectious cDNA Clone of North American Porcine reproductive and Respiratory Syndrome (PRRS) Virus and Uses Thereof - The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules. | 02-17-2011 |
| 20110040080 | Infectious cDNA Clone of North American Porcine Reproductive and Respiratory Syndrome (PRRS) Virus and Uses Thereof - The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus. These viral vectors and transfected host cell lines are useful in providing peptides to compensate for mutated peptide coding sequences of DNA sequences encoding genetically-modified North American PRRS viruses so that functional virions can be generated. | 02-17-2011 |
| 20110092688 | NUCLEIC ACID CONSTRUCT CONTAINING A NUCLEIC ACID DERIVED FROM THE GENOME OF HEPATITIS C VIRUS (HCV) OF GENOTYPE 2a, AND A CELL HAVING SUCH NUCLEIC ACID CONSTRUCT INTRODUCED THEREIN - The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5′ untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3′ untranslated region on the genomic RNA of hepatitis C virus of genotype 2a. | 04-21-2011 |
| 20110098459 | Isolated Nucleic Acid Molecules From Transgenic Papaya Line 18-2-4 Resistant To Papaya Ringspot Virus And Use Thereof - Provided is an isolated nucleic acid molecule having a right border flanking region, a left border flanking region and a transgene sequence between the right border flanking region and the left border flanking region, wherein the right border flanking region having at least 90% homology with the sequence set forth in SEQ ID NO: 30; the left border flanking region having at least 90% homology with the sequence set forth in SEQ ID NO: 32; and the transgene sequence having a | 04-28-2011 |
| 20130158246 | OPTIMIZED PROMOTER SEQUENCE - A modified CAG promoter which is capable of driving high levels of expression of sequences of interest inserted downstream therefrom is herein described. | 06-20-2013 |
| 20130296541 | Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions - The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also contains the preparation of immunogenic compositions using said cDNA. | 11-07-2013 |
| 20130345414 | TREATING CANCER WITH VIRAL NUCLEIC ACID - This document provides methods and materials related to the use of nucleic acid coding for viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, methods for making engineered viral nucleic acid, methods for identifying infectious nucleic acid for treating cancer, methods and materials for controlling virus-mediated cell lysis, and methods and materials for assessing the control of virus-mediated cell lysis are provided. | 12-26-2013 |
| 20140221636 | Bovine Adeno-Associated Viral (BAAV) Vector and Uses Thereof - The present invention provides a bovine adeno-associated virus (BAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the BAAV vectors and particles. | 08-07-2014 |
| 20140316122 | HEPATITIS B VIRUS VACCINES - This document provides methods and materials for producing immune responses against hepatitis B viruses. For example, polypeptides, nucleic acid molecules encoding such polypeptides, virus-like particles containing such polypeptides, vaccine preparations containing one or more polypeptides provided herein, vaccine preparations containing one or more nucleic acid molecules provided herein, vaccine preparations containing one or more virus-like particles provided herein, and methods for inducing immune responses against hepatitis B viruses within mammals (e.g., humans) are provided. | 10-23-2014 |
